Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00770120 · ClinicalTrials.gov registry record · Phase 2
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT00770120 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 61 participants.
The verdict
NCT00770120, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with pleural malignant mesothelioma that cannot be removed by surgery.
Interventions
- DRUG everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2008-12 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00770120
The ClinicalTrials.gov registry entry for NCT00770120 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which everolimus is the first listed.
NCT00770120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00770120 about?
NCT00770120 is a clinical study titled "S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery". RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with pleural malignant mesothelioma that cannot be removed by surgery.
What is the current status of trial NCT00770120?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2008-12. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00770120?
The interventions under investigation include: everolimus (DRUG).
Who is sponsoring clinical trial NCT00770120?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.